Product Details for ANDA 209721
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE)
100MG;150MG
Marketing Status: Prescription
133MG;200MG
Marketing Status: Prescription
167MG;250MG
Marketing Status: Prescription
200MG;300MG
Marketing Status: Prescription
100MG;150MG
Marketing Status: Prescription
Active Ingredient: EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Proprietary Name: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 100MG;150MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A209721
Product Number: 001
Approval Date: Aug 22, 2018
Applicant Holder Full Name: AMNEAL PHARMACEUTICALS CO GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE)
Proprietary Name: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 100MG;150MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A209721
Product Number: 001
Approval Date: Aug 22, 2018
Applicant Holder Full Name: AMNEAL PHARMACEUTICALS CO GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
133MG;200MG
Marketing Status: Prescription
Active Ingredient: EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Proprietary Name: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 133MG;200MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A209721
Product Number: 002
Approval Date: Aug 22, 2018
Applicant Holder Full Name: AMNEAL PHARMACEUTICALS CO GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE)
Proprietary Name: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 133MG;200MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A209721
Product Number: 002
Approval Date: Aug 22, 2018
Applicant Holder Full Name: AMNEAL PHARMACEUTICALS CO GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
167MG;250MG
Marketing Status: Prescription
Active Ingredient: EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Proprietary Name: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 167MG;250MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A209721
Product Number: 003
Approval Date: Aug 22, 2018
Applicant Holder Full Name: AMNEAL PHARMACEUTICALS CO GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE)
Proprietary Name: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 167MG;250MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A209721
Product Number: 003
Approval Date: Aug 22, 2018
Applicant Holder Full Name: AMNEAL PHARMACEUTICALS CO GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
200MG;300MG
Marketing Status: Prescription
Active Ingredient: EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Proprietary Name: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 200MG;300MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A209721
Product Number: 004
Approval Date: Aug 22, 2018
Applicant Holder Full Name: AMNEAL PHARMACEUTICALS CO GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 200MG;300MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A209721
Product Number: 004
Approval Date: Aug 22, 2018
Applicant Holder Full Name: AMNEAL PHARMACEUTICALS CO GMBH
Marketing Status: Prescription
Patent and Exclusivity Information